Mirikizumab plus tirzepatide for UC with obesity
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests whether adding mirikizumab to the weight-loss drug tirzepatide helps people with moderate-to-severe ulcerative colitis who also have obesity or overweight. It aims to see if the combination reduces bowel inflammation and helps with weight management.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with ulcerative colitis for at least 3 months.
- Your UC should be moderately to severely active, meaning you have symptoms like frequent diarrhea, bleeding, and inflammation seen on a colonoscopy.
- You must have obesity (BMI 30 or higher) or be overweight (BMI 27 or higher) with a weight-related condition like high blood pressure, type 2 diabetes, high cholesterol, sleep apnea, or heart disease.
- You must have tried at least one UC treatment (like steroids, mesalamine, or a biologic) and it didn't work well enough or you couldn't tolerate it.
- You cannot have type 1 diabetes or type 2 diabetes that requires insulin, and you must not have had a recent serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two study drugs, mirikizumab and tirzepatide, in people with moderate to severe Crohn's disease who also have overweight or obesity. The goal is to see if these treatments can help control Crohn's symptoms and inflammation.
This study follows people with ulcerative colitis who are starting or have just started mirikizumab treatment. It aims to understand how well the drug works in real-world settings and how patients do over the next 12 months.
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
This study tests two experimental drugs, Eltrekibart and Mirikizumab, for adults with moderate to severe ulcerative colitis who have not responded well to other treatments. The goal is to see if these drugs can help control the disease.
This study tests two drugs together (LY4268989 and mirikizumab) in people with moderate to severe ulcerative colitis. It's for those whose current treatments didn't work well enough.
This trial tests if starting with the stronger drug mirikizumab (top-down therapy) works better than the usual treatment with azathioprine for people newly diagnosed with moderate-to-severe ulcerative colitis. It aims to see which approach controls inflammation and improves symptoms faster.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.